This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management.

This book presents the latest research on speech biomarkers and demonstrates the benefits of quantitative measurement technology for emotion and stress in clinical settings. It begins with an introduction and details the validation of a technique for assessing emotions using voice biomarkers. This technology evaluates stress levels, which affect emotional expression and lead to changes in certain voice qualities. It further explains how a voice emotion recognition system can effectively detect illnesses such as anxiety disorders, depression, bipolar disorder, PTSD, Parkinson’s disease, dementia, and more. Beyond clinical applications, it is also useful for the mental care of athletes and assessing driving skills. Voice biomarkers can be easily, non-invasively, and remotely measured, offering excellent cost efficiency. This book lays the groundwork for addressing unresolved issues and advancing further.

"Voice Biomarkers - Current Status and Issues in the Development" is an invaluable resource for healthcare professionals at all levels, especially those involved in pathophysiology, disaster psychology, mental health, and social medicine. Researchers in engineering will also find this book insightful.

This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management.

This book presents the latest research on speech biomarkers and demonstrates the benefits of quantitative measurement technology for emotion and stress in clinical settings. It begins with an introduction and details the validation of a technique for assessing emotions using voice biomarkers. This technology evaluates stress levels, which affect emotional expression and lead to changes in certain voice qualities. It further explains how a voice emotion recognition system can effectively detect illnesses such as anxiety disorders, depression, bipolar disorder, PTSD, Parkinson’s disease, dementia, and more. Beyond clinical applications, it is also useful for the mental care of athletes and assessing driving skills. Voice biomarkers can be easily, non-invasively, and remotely measured, offering excellent cost efficiency. This book lays the groundwork for addressing unresolved issues and advancing further.

"Voice Biomarkers - Current Status and Issues in the Development" is an invaluable resource for healthcare professionals at all levels, especially those involved in pathophysiology, disaster psychology, mental health, and social medicine. Researchers in engineering will also find this book insightful.